Revance Therapeutics Inc. | Mutual Funds
Mutual Funds that own Revance Therapeutics Inc.
JPMorgan Growth Advantage Fund
1,172,200
3.17%
0
0.34%
07/31/2018
Franklin Small Cap Growth Fund
871,492
2.36%
-62,308
0.8%
03/31/2018
Vanguard Total Stock Market Index Fund
825,369
2.23%
0
0%
07/31/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
794,771
2.15%
-148,800
0.94%
06/30/2018
Dreyfus Opportunistic Small Cap Fund
733,734
1.99%
-16,801
1.6%
04/30/2018
iShares Russell 2000 ETF
686,934
1.86%
-366
0.04%
09/06/2018
JPMorgan Funds - Global Healthcare Fund
632,991
1.71%
0
0.59%
05/31/2018
Franklin Biotechnology Discovery Fund
606,200
1.64%
14,000
1.13%
03/31/2018
Canada Pension Plan
583,000
1.58%
0
0.01%
03/31/2018
JPMorgan Small Cap Growth Fund
564,972
1.53%
0
0.62%
07/31/2018
| Address |
7555 Gateway Boulevard
Newark California 94560
United States
|
|
Employees
|
- |
| Website |
http://www.revance.com |
| Updated |
07/08/2019 |
| Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. |
